EAN 2026: Bocunebart’s promise as migraine preventive in treatment-refractory patients
Bocunebart's PACAP-targeting mechanism positions it as a potential first-in-class therapy in a thin pipeline of novel late-stage candidates.
Therapy Area
Sanofi aims for Nexviazyme approval in younger Pompe disease patients
EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s
ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1
EHA26: Epcoritamab improves PFS but not OS in R/R LBCL
ECRD 2026: Europe’s rare disease bottleneck is funding rather than science
Parabilis Medicines sets biotech record with $670m IPO
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
